Literature DB >> 8276057

Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin.

K H Lee1, J G Shin, W S Chong, S Kim, J S Lee, I J Jang, S G Shin.   

Abstract

We have investigated changes in the pharmacokinetics of prednisolone caused by co-administration or discontinuation of rifampin. Serial IV pharmacokinetic studies of prednisolone (1 mg/kg) in groups of 3 patients over a 1 month period of rifampin co-treatment or after its withdrawal, revealed significant changes in the area under the curve, the total clearance, the non-renal clearance and the half-life. The changes in the pharmacokinetic parameters reached a 1.5 to 2-fold plateau after 2 weeks and the half maximal effect was attained within 5 days. Neither the volume of distribution nor the protein binding of prednisolone were significantly altered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8276057     DOI: 10.1007/bf00315399

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Dose-dependent prednisolone kinetics.

Authors:  A Tanner; F Bochner; J Caffin; J Halliday; L Powell
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  Letter: Rifampicin and cortisone replacement therapy.

Authors:  D N Maisey; R C Brown; J L Day
Journal:  Lancet       Date:  1974-10-12       Impact factor: 79.321

3.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

4.  Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function.

Authors:  G A Buffington; J H Dominguez; W F Piering; L A Hebert; H M Kauffman; J Lemann
Journal:  JAMA       Date:  1976-10-25       Impact factor: 56.272

5.  Altered prednisolone pharmacokinetics in patients treated with rifampicin.

Authors:  H Bergrem; O K Refvem
Journal:  Acta Med Scand       Date:  1983

6.  The antagonistic effect of rifampin upon cyclosporine bioavailability.

Authors:  D Van Buren; C A Wideman; M Ried; S Gibbons; C T Van Buren; M Jarowenko; S M Flechner; O H Frazier; D A Cooley; B D Kahan
Journal:  Transplant Proc       Date:  1984-12       Impact factor: 1.066

7.  Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome.

Authors:  W Hendrickse; J McKiernan; M Pickup; J Lowe
Journal:  Br Med J       Date:  1979-02-03

8.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Prednisolone clearance at steady state in dogs.

Authors:  F J Frey; B M Frey; A Greither; L Z Benet
Journal:  J Pharmacol Exp Ther       Date:  1980-11       Impact factor: 4.030

10.  Rifampicin reduces effectiveness and bioavailability of prednisolone.

Authors:  W A McAllister; P J Thompson; S M Al-Habet; H J Rogers
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-19
View more
  12 in total

1.  Effect of rifampicin on the pharmacokinetics of pioglitazone.

Authors:  Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 2.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Experience in the diagnosis and treatment of a drug-induced pemphigus.

Authors:  Pei Yang Yuan; Min Qiu; Zi Xin Wan; Lu Jiang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-12-01

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

Authors:  B Blumberg; W Sabbagh; H Juguilon; J Bolado; C M van Meter; E S Ong; R M Evans
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

7.  Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.

Authors:  Vianney Tuloup; Mathilde France; Romain Garreau; Nathalie Bleyzac; Laurent Bourguignon; Michel Tod; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

8.  Role of cytochrome P450 in drug interactions.

Authors:  Zakia Bibi
Journal:  Nutr Metab (Lond)       Date:  2008-10-18       Impact factor: 4.169

Review 9.  Pharmacokinetic drug-drug interaction and their implication in clinical management.

Authors:  Caterina Palleria; Antonello Di Paolo; Chiara Giofrè; Chiara Caglioti; Giacomo Leuzzi; Antonio Siniscalchi; Giovambattista De Sarro; Luca Gallelli
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

10.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.